Last Updated: June 19, 2025

Expanded Access Policy

BioAegis is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families and patient communities through education, empathy, and awareness.

Consistent with BioAegis’s mission to bring innovative medicines to patients with serious or life-threatening illnesses or conditions, we are focused on enrolling and conducting the clinical trials necessary to gain regulatory approvals to make our medicines available broadly to patients as quickly as possible. We are privileged to collaborate with clinical investigators and with patients who participate in our studies to develop new, safe and effective therapies. We believe this approach will best serve patients who could be helped by the therapies we are developing.

At this time, we have made the decision not to offer Expanded Access for recombinant human plasma gelsolin (rhu-pGSN) outside our randomized clinical trials.